MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

AbbVie Inc

Open

SectorGezondheidszorg

185.11 2.66

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

178.98

Max

186.19

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.6B

-23M

Verkoop

642M

15B

K/W

Sectorgemiddelde

71.496

57.333

EPS

2.16

Dividendrendement

3.86

Winstmarge

-0.152

Werknemers

55,000

EBITDA

-4.4B

535M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+17.54% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.86%

2.63%

Volgende Winsten

25 apr 2025

Volgende dividenddatum

15 mei 2025

Volgende Ex Dividend datum

14 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-29B

306B

Vorige openingsprijs

182.45

Vorige sluitingsprijs

185.11

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

AbbVie Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 apr 2025, 18:18 UTC

Belangrijke Marktbewegers

Pharma Shares Reverse Losses After Tariff Pause

9 apr 2025, 09:39 UTC

Belangrijke Marktbewegers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27 feb 2025, 22:48 UTC

Acquisities, Fusies, Overnames

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 feb 2025, 13:41 UTC

Belangrijke Marktbewegers

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31 jan 2025, 13:28 UTC

Winsten

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 mrt 2025, 15:04 UTC

Acquisities, Fusies, Overnames

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb 2025, 13:25 UTC

Top Nieuws
Winsten

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Winsten

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 feb 2025, 12:00 UTC

Top Nieuws

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 jan 2025, 15:50 UTC

Top Nieuws
Winsten

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 jan 2025, 13:51 UTC

Winsten

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31 jan 2025, 13:47 UTC

Top Nieuws
Winsten

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 jan 2025, 13:24 UTC

Marktinformatie
Winsten

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31 jan 2025, 12:46 UTC

Winsten

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31 jan 2025, 12:39 UTC

Winsten

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31 jan 2025, 12:38 UTC

Winsten

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31 jan 2025, 12:38 UTC

Winsten

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31 jan 2025, 12:37 UTC

Winsten

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31 jan 2025, 12:37 UTC

Winsten

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q Loss $22M >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q Adj EPS $2.16 >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31 jan 2025, 12:36 UTC

Winsten

AbbVie 4Q Loss/Shr 2c >ABBV

Peer Vergelijking

Prijswijziging

AbbVie Inc Prognose

Koersdoel

By TipRanks

17.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 212 USD  17.54%

Hoogste 241 USD

Laagste 190 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor AbbVie Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

13

Buy

5

Hold

0

Sell

Technische score

By Trading Central

174.2 / 180.5Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.